March 11, 2007 -- The best thing about last week was that it was better than the week before. After dropping 5.7% two weeks ago, the Centient Biotech 200™ gained just one net point over the five sessions to end at 3823, a rise of .03%. Breadth swung back to the modestly positive side and was fully in line with a slightly firmer biotech sector. No biotechs made their IPOs last week, but Tongjitang Chinese Medicines is on the schedule for the coming week. Recent IPOs continue to outperform the CBT 200™. On the CBT 200™ list, La Jolla Pharma was far and away the best performer, rising 91% on interim trial data, and Tercica climbed 19% after winning a patent infringement suit against Insmed. More details...
